- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05166317
Comparative Efficacy of Various Non-invasive Methods in Assessing Response to Beta-blockers as Secondary Prophylaxis for Acute Variceal Bleed.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Aim:
To determine the diagnostic accuracy of non-invasive tests in predicting response to NSBB for secondary prophylaxis of variceal bleed at 6wks.
Primary objective:
To compare the diagnostic accuracy of non-invasive modalities in correctly predicting response to beta-blockers as compared with HVPG in preventing variceal rebleed at 6 weeks.
Secondary objectives:
- Assessment of severity of portal hypertension by non-invasive methods.
- Correlation and Cut-off values for non-invasive methods in responders and non-responders.
- AAR, APRI, FIB-4 index, CSPH risk score,fibrosis index, GPR, King's score, Lok score are other non- invasive tests.
- Correlation between HVPG &non invasive test, responder and non-responder.
- Comparison ofhypersplenism(Splenic volume and area) and hematological parameters before and after treatment.
- Diagnosis and response assessment by convolutional neural network- AI based model.
- Prognostic implication of HVPG rebleed on EVL+beta-blockers.
Methodology:
- Study population:All the consecutive patients of cirrhosis admitted to Intensive care unit of Hepatology department of ILBS will be evaluated for inclusion
- Study design: Prospective observational study. The study will be conducted in Department of Hepatology ILBS.
- Study period: 1.5 years
- Sample size: Assuming that Sn of 92%, α of 5%, Power 80, we need to have 186 patients. So we decided to enroll ~200 cases (Including 5% defaulter rate)
Intervention:
- HVPG done at the baseline within 5days of acute variceal bleed and at 6weeks
- Endoscopic variceal band ligation at 3rd week
- NSBB started on day 6 which optimised according to heart rate and continued for 6 weeks.
- Monitoring and assessment
Patients with acute variceal bleed after endovariceal band ligation will be undergoing HVPG, TE to measure splenic stiffness and baseline investigations such as complete blood count, liver and kidney function test, ultrasonography of the abdomen, contrast enhanced computerized tomography of abdomen. These investigations will be carried out within 5days. After 5 days NSBB is started and is optimsed to maximum dose according to heart rate and blood pressure. After 3 weeks EVL is done. After 6 weeks of NSBB, after 3weeks of secondary EVL;HVPG, TE to measure liver and splenic stiffness and other baseline investigations are done.
• Hepatic venous pressure gradient (HVPG):
- Prior to the HVPG measurement, a venous access was performed under ultrasonography after local anesthesia. The Seldinger technique was used to insert a catheter into the right brachial vein or the right internal jugular vein. An occlusion balloon catheter of 6 F was guided in a branch of the hepatic veins, usually the median or right vein, under fluoroscopic control and continuous electrocardiographic and pressure monitoring.
- After inflating the balloon at the catheter's tip (maximum diameter ranges from 8.5-11.5 mm), a venous check was performed to demonstrate complete vessel occlusion. The wedged hepatic vein pressure (WHVP) was measured in this condition. Following that, the free hepatic vein pressure (FHVP) was measured after deflating the balloon at the catheter's tip. On a multi-channel recorder, a permanent trace was obtained. Pressures were also achieved in the inferior vena cava and the right atrium. According to the Baveno VI consensus, the HVPG-response was defined as a 20% or 12 mmHg reduction in HVPG after NSBB treatment.
HVPG= WHVP - FHVP (Normal is <5mm of Hg)
• Ultrasonography of the abdomen:
- dilated portal vein (>13 mm): non-specific
- biphasic or reverse flow in portal vein (late stage): pathognomonic
- recanalization of paraumbilical vein: pathognomonic
- portal-systemic collateral pathways (collateral vessels/varices)
- splenomegaly
- ascites
- The damping index (showing changes in the doppler hepatic vein waveform) corresponds with hemodynamically significant portal hypertension and HVPG values (together with HVPG changes after treatment)
splenic arterial resistive index
• Liver and splenic stiffness:
- A 3.5-MHz ultrasound transducer probe is mounted on the axis of a vibrator in the FibroScan device. Mild amplitude, low-frequency (50 Hz) vibrations are transmitted to the liver tissue, causing an elastic shear wave to propagate through the underlying tissue.If the success rate was greater than 60% and the interquartile range (IQR) was greater than 30% of the median value, LS values were accepted.
Guidelines for measuring SS is same as LS. SS was performed on a supine patient with maximal abduction of the left arm, with the probe positioned in an intercostal space where the spleen was correctly visualized by US. Furthermore, in accordance with the FibroScan's technical features, patients with a splenic parenchymal thickness of >4 cm under the probe were excluded.
• Radiomics:
- Convolutional neural network - Deep learning using liver and splenic channels for assessment of portal hypertension.
- STATISTICAL ANALYSIS:
- Continuous variables are expressed as the median and categorical data as numbers (percentages) (range). For group comparison, use the Mann-Whitney test for continuous variables and the 2 test for categorical variables. The Pearson correlation coefficient will be used to assess the linear relationship between noninvasive tests and HVPG (r). Receiver operating characteristic (ROC) curves will be computed for each of the diagnostic parameters evaluated (age, transaminases, platelet count, spleen diameter, Plt/Spl, LS, SS, LSPS), as well as the area under the ROC curve (AUROC).For all tests, p≤ 0.05 will be considered statistically significant. Analysis will be performed using SPSS .The analysis will be done with intention to treat and per protocol analysis if applicable.
- Adverse effects:
- 1. Major Sideeffects of Betablockers
- Bradycardia,Heart block
- Hyperglycaemia
- Heart failure
- Increase in airway resistance
- Worsening lipid profile
Exacerbration of peripheral vascular disease
2. HVPG related complications
- Transient arrhythmias
- Vagal reaction
- Local access pain and bleeding
- Stopping rule: Development of serious adverse effects leading to withdrawal of the drug or death from any cause.
Tipo di studio
Iscrizione (Anticipato)
Contatti e Sedi
Contatto studio
- Nome: Dr Akhil Deshmukh, MD
- Numero di telefono: 01146300000
- Email: akhildeshmukh52@gmail.com
Luoghi di studio
-
-
Delhi
-
New Delhi, Delhi, India, 110070
- Institute of liver and Biliary Sciences
-
Contatto:
- Dr. Akhil Deshmukh, MD
- Numero di telefono: 011-46300000
- Email: akhildeshmukh52@gmail.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Clinical / radiological /histologic diagnosis of cirrhosis (Child A&B)
- Age >18 years
- Advanced compensated liver disease of different etiology(Viral,metabolic,alcoholic)
- Upper GI bleed
- Valid consent
- No history of NSBB use in last 6 weeks
Exclusion Criteria:
- Age > 70 years
- Portal vein thrombosis
- Underlaying shunts
- Spleen anteroposterior diameter <4cm
- Non cirrhotic portal hypertension
- Only PHG, Ectopic varices
- Heart rate <50bpm, SBP<100mm of Hg,Asthma, COPD, Aortic disease, atrioventricular block, Peripheral vascular disease.
- Pregnancy
- obese(BMI>30mm of Hg)
- HIV
- HCC / Other malignancy
- Other Comorbidities: Chronic kidney disease [ CrCl< 30] Cirrhosis : Child C Stroke Cardiac failure, Uncontrolled diabetes(HbA1c >9)
- AST/ALT >5 times
- Drug allergies
- ACLF
- Narrow intercoastal space
- Failure to give informed consent from family members.
- Patient enrolled in other clinical study
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: Solo caso
- Prospettive temporali: Prospettiva
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
---|---|
Liver Cirrhosis
All the consecutive patients of cirrhosis admitted to Intensive care unit of Hepatology department of ILBS.
|
Questo è uno studio osservazionale
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Change in HVPG and its correlation with non-invasive methods.
Lasso di tempo: 6 Weeks
|
6 Weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Assessment of severity of portal hypertension by non-invasive methods.
Lasso di tempo: 6 weeks
|
6 weeks
|
|
Correlation and Cut-off values for non-invasive methods in responders and non-responders in relation to HVPG.
Lasso di tempo: 6 weeks
|
Non invasive methods - LSM,SSM & LSPS
|
6 weeks
|
Correlation of Serological and radiological non invasive tests response in comparison with HVPG.
Lasso di tempo: 6 weeks
|
AAR, APRI, FIB-4 index, CSPH risk score,fibrosis index, GPR, King's score, Lok score are other non- invasive tests.
|
6 weeks
|
Comparison of hypersplenism (Splenic volume and area) and hematological parameters before and after treatment.
Lasso di tempo: 6 weeks
|
6 weeks
|
|
Diagnosis and response assessment by convolutional neural network- AI based model.
Lasso di tempo: 6 weeks
|
6 weeks
|
|
Prognostic implication of HVPG rebleed on EVL+beta-blockers.
Lasso di tempo: 6 weeks
|
6 weeks
|
Collaboratori e investigatori
Studiare le date dei record
Studia le date principali
Inizio studio (Anticipato)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- ILBS-Bleed-01
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Acute Variceal Bleed
-
Region of Southern DenmarkOdense Municipality, Denmark; Kerteminde Municipality, Denmark; Svendborg Municipality...Completato
-
Peking University Third HospitalShanghai Jiao Tong University School of MedicineAttivo, non reclutante
-
University of Southern DenmarkCompletatoCondizioni mediche acuteDanimarca
-
AstraZenecaCompletatoRiacutizzazioni acute della BPCOCina
-
Assiut UniversityCompletato
-
Central Hospital, Nancy, FranceSconosciutoCondizioni acute in terapia intensivaFrancia
-
Centre Hospitalier Universitaire de NiceCompletato
-
GlaxoSmithKlineCompletato
-
Vanderbilt UniversityTerminatoLesioni polmonari, acuteStati Uniti
-
Children's Hospital of PhiladelphiaNational Heart, Lung, and Blood Institute (NHLBI)CompletatoLesioni polmonari acute pediatricheStati Uniti